Skip to main content
. 2013 Aug 28;9:1273–1280. doi: 10.2147/NDT.S48158

Table 6.

Summary of treatment difference for MADRS responders and remitters at week 8 (ITT–LOCF)

Treatment group n MADRS responder
MADRS remitter
Responders (%) Difference (%) vs placebo 95% CI for difference (%) Remitters (%) Difference (%) vs placebo 95% CI for difference (%)
Placebo 186 86 (46.2) 53 (28.5)
BUP150 190 98 (51.6) −5.3 −15.4, 4.7 60 (31.6) −3.1 −12.3, 6.2
BUP300 188 82 (43.6) 2.6 −7.5, 12.7 56 (29.8) −1.3 −10.5, 7.9

Notes: An MADRS responder is defined as a subject with a ≥50% reduction from baseline in the MADRS total score at week 8. MADRS remitter is defined as a subject with ≤11 MADRS total score at week 8.

Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; SR, sustained release; vs, versus; n, number.